TRIB - Trinity Biotech plc

TRIB - Trinity Biotech plc

https://www.trinitybiotech.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Trinity Biotech Appoints Paul Tivnan as Non-Executive Director - Trinity Biotech ( NASDAQ:TRIB )

Benzinga • 3 weeks, 4 days ago • score: 0.35

DUBLIN, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Trinity Biotech plc TRIB, a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Paul Tivnan to its Board of Directors as a ...

Trinity Biotech Appoints Paul Tivnan as Non-Executive Director

GlobeNewswire • 3 weeks, 4 days ago • score: 0.23

DUBLIN, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Trinity Biotech plc ( Nasdaq: TRIB ) , a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Paul Tivnan to its Board of Directors as a ...

Regulatory Approval Granted for Commencement of Trinity Biotech's Offshored and Outsourced Manufacturing of its Flagship Rapid HIV Test, Facilitating Strategic and Financial Performance Transformation - Trinity Biotech ( NASDAQ:TRIB )

Benzinga • 3 weeks, 5 days ago • score: 0.24

Approval Facilitates Immediate Offshored and Outsourced Manufacturing Strategic Offshore Manufacturing Move Expected to Drive Gross Margin Expansion, Free Up Working Capital, and Enhance Scalability Transition to Outsourced Production Reduces Fixed Costs and Supports Trinity's Broader ...

Regulatory Approval Granted for Commencement of Trinity Biotech's Offshored and Outsourced Manufacturing of its Flagship Rapid HIV Test, Facilitating Strategic and Financial Performance Transformation

GlobeNewswire • 3 weeks, 5 days ago • score: 0.26

Approval Facilitates Immediate Offshored and Outsourced Manufacturing ...

Trinity Biotech's Redesigned CGM Sensor Favored by New Clinical Data

Zacks Commentary • 1 month ago • score: 0.32

TRIB's needle-free CGM+ sensor shows accurate 15-day results with no calibration, slashing costs and boosting access.

Trinity Biotech Achieves Breakthrough Clinical Trial Results for Redesigned CGM Sensor - Trinity Biotech ( NASDAQ:TRIB )

Benzinga • 1 month ago • score: 0.32

DUBLIN, Aug. 12, 2025 ( GLOBE NEWSWIRE ) -- Trinity Biotech plc TRIB, a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced compelling positive clinical trial results demonstrating a major technical ...

Trinity Biotech Achieves Breakthrough Clinical Trial Results for Redesigned CGM Sensor

GlobeNewswire • 1 month ago • score: 0.24

Clinical data confirms elimination of requirement for finger-stick calibration, de-risking pathway to commercialization for the company's next-generation CGM+ biosensor platform Clinical data confirms elimination of requirement for finger-stick calibration, de-risking pathway to ...

Trinity Biotech Announces Launch of FDA-cleared Preeclampsia Testing Service - Trinity Biotech ( NASDAQ:TRIB )

Benzinga • 1 month, 1 week ago • score: 0.21

FDA-cleared PreClara™ Ratio ( sFlt-1/PlGF ) biomarker test offers clinicians a crucial tool for managing hypertensive disorders of pregnancy, with potential significant cost savings and improved patient outcomes

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Trinity Biotech plc acquires, develops, manufactures and markets medical diagnostic products for the clinical laboratory and point of care (POC) segments of the diagnostic market in the United States, Africa, Asia and Europe. The company is headquartered in Bray, Ireland.

52W High

$2.21

52W Low

$0.48

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.96

Valuation

As of 2024-12-31 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-6.06

EV/Revenue (<3 favorable)

1.62

P/S (TTM) (<3 favorable)

0.07

P/B (<3 favorable)

5.11

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

12.01%

Institutions (25–75% balanced)

13.95%

Shares Outstanding

3,726,400

Float

134,009,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

2015-06-05

Income & Growth

Profitability: Weak

As of 2024-12-31 (Overview)

Revenue (TTM)

61,555,000

Gross Profit (TTM)

21,441,000

EPS (TTM)

-1.80

Profit Margin (>10% good)

-0.52%

Operating Margin (TTM) (higher better)

-0.43%

ROE (TTM) (>15% strong)

-19.13%

EPS YoY (Quarterly) (>10% good)

-0.77

Revenue YoY (Quarterly) (>8% good)

0.18

Momentum

Bearish momentum

Value

0.0057

Previous

0.0117

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025